SCHEDULE 8Consequential provision

PART 1Amendment of primary legislation

Amendment of the Access to Medical Treatments (Innovation) Act 2016I12

In section 3(2)(b) and (4)(a), (b) and (c) of the Access to Medical Treatments (Innovation) Act 2016 M1 (provision supplementary to section 2: database of innovative treatments) insert “ UK ” before “marketing authorisation”.